NGS-MRD Panel Is “Highly Sensitive, Accurate” in AML

News
Article

A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia.

A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia.

A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia.

Korean researchers have developed a next-generation sequencing (NGS) panel for measuring MRD in patients with acute myeloid leukemia (AML) that they say is highly sensitive, accurate, could be applied in clinical practice to about 78% of AML patients with somatic mutations identified at diagnosis, and could detect clones emerging during relapse early, thus improving prognoses. The study is published in the July issue of Annals of Laboratory Medicine.

The researchers used the panel to retrospectively sequence 54 cryopreserved bone marrow or peripheral blood samples from 23 patients diagnosed with AML at Yonsei University Severance Hospital in Seoul, South Korea, between January 2018 and March 2020. Based on the most recent 4 years of data on diagnostic panel testing in their institution’s internal database, they selected 24 genes for the panel.

Twenty patients (excluding 3 lost to follow-up) were evaluated after a mean follow-up period of 945.1 days. MRD positivity was associated with poor outcomes, with median progression-free and overall survival of 26.7 and 21.3 months, respectively, for MRD-positive patients compared with 41.3 and 38.1 months, respectively for those who were MRD negative.

“The test reproducibly detected MRD in three dilution series samples, with a sensitivity of 0.25% for single-nucleotide variants. More than half of samples from patients with morphologic remission after one month of chemotherapy had detectable mutations,” the authors, led by June-Won Cheong, MD, PhD, and Saeam Shin, MD, PhD, wrote. Limitations of the study include a relatively small sample size and the selection of panel genes based on data from a single institution, they wrote.

Reference

Kim JJ, Jang JE, Lee HA, et al. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia. Ann Lab Med. 2023;43(4):328-336. doi:10.3343/alm.2023.43.4.328

Recent Videos
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Related Content
Phase 1 data related to CLN-049 for patients with acute myeloid leukemia will be presented at the 2025 ASH Annual Meeting and Exposition.

FDA Grants Fast Track Designation to Novel FLT3/CD3 Bispecific in R/R AML

Russ Conroy
December 2nd 2025
Article

Phase 1 data related to CLN-049 for patients with acute myeloid leukemia will be presented at the 2025 ASH Annual Meeting and Exposition.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

American Society for Transplantation and Cellular Therapy
November 24th 2025
Article

Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Among all patients with AML enrolled in the trial who received olutasidenib, the CR or CRh rate was 35%, with 55% of responders responding within 2 months.

Olutasidenib Maintains Durable Responses in IDH1+ AML for 5 Years

Tim Cortese
November 19th 2025
Article

Among all patients with AML enrolled in the trial who received olutasidenib, the CR or CRh rate was 35%, with 55% of responders responding within 2 months.

Based on results from the ANDROMEDA study, the FDA has given traditional approval to daratumumab and hyaluronidase-fihj plus VCd in patients with newly diagnosed light chain amyloidosis.

FDA Traditionally Approves Daratumumab Regimen in AL Amyloidosis

Tim Cortese
November 19th 2025
Article

Based on results from the ANDROMEDA study, the FDA has given traditional approval to daratumumab and hyaluronidase-fihj plus VCd in patients with newly diagnosed light chain amyloidosis.